KAWASHIMA D et al.
VH is a serious complication of PDR and results in severe loss of vision. It is a sight-threatening complication in DR patients that, in persistent cases, requires vitreous surgery. Progression of DR involving VH can take place in diabetic patients after coronary revascularization either with percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG), but little is known about the prevalence of VH after coronary revascularization. It appears that a large number of DR patients who are at risk of VH undergo coronary revascularization, so the issue of post-revascularization VH is important both cardiologists and cardiac surgeons. The purpose of this retrospective study was to assess the prevalence of VH after coronary revascularization among patients with DR.
Methods
Between April 2004 and September 2008, 2,820 consecutive patients underwent either CABG or PCI with drug-eluting stent (DES) implantation for coronary revascularization at The University of Tokyo Hospital, Tokyo, Japan. The patients were scheduled to undergo elective PCI with DES implantation while receiving 100 mg/day of aspirin and the Japanese standard dose of a thienopyridine (200 mg/day of ticlopidine for at least 7 days or a 300 mg loading dose, followed by 75 mg/day, of clopidogrel for at least 1 day). All patients continued to receive aspirin (100 mg/day) after coronary revascularization, and thienopyridine treatment (clopidogrel 75 mg/day or ticlopidine 200 mg/day) was mandatory for at least 1 year in patients who had undergone DES implantation. Patients were eligible for inclusion in this study if: (1) they were considered to have DM (ie, if they were having medical treatment with hypoglycemic agents or insulin injection, or if they had hemoglobin (Hb) A1c >6.5% at the time of revascularization) and (2) they had undergone an ophthalmic examination in the Department of Ophthalmology for detection and treatment of retinopathy within the year prior to revascularization. Patients were excluded if they needed concomitant major surgery (eg, valve surgery, resection of a left ventricular aneurysm, resection of a malignant tumor, or implantation of a left ventricular assist device). A total of 151 patients met the criteria. Their ophthalmologic records, including ophthalmologic charts, fundus photographs, and fluorescein retinal angiography, were reviewed to evaluate retinal status. We used the most recent ophthalmologic records up to the time of coronary revascularization to approximate the status of DR at the time of the procedure. According to a modification of the Diabetic Retinopathy 
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Study grading scale, the status in the worst affected eye at the time of coronary revascularization was used, and DR patients were classified into 2 groups: NPDR (retinal hemorrhage, soft exudates, hard exudates, intraretinal microvascular abnormalities, or venous beading) and PDR (the presence of new vessels, preretinal hemorrhage, history of VH, rubeotic glaucoma, tractional retinal detachment, panretinal photocoagulation (PRP) scars, and history of vitrectomy). 6 The patients' base-line characteristics (demographic data, medical history, coronary risk factors, and revascularization procedures) were collected from medical and surgical records. Every patient had undergone an ophthalmological check approximately 1 month after coronary revascularization. The incidence of VH was determined by a review of hospital ophthalmologic records. Patients who had hyphema, preretinal hemorrhage or VH (or any combination of these) after coronary revascularization were counted because both hyphema and preretinal hemorrhage originate from new vessels in PDR and could lead to visual impairment, as well as VH. For these patients, we also recorded visual acuity both during VH and at the last outpatient clinic examination on October 31, 2008. The findings reported in this study are those recorded for all patients as of that date.
Statistical Analysis
The data was analyzed using statistical software JMP 8 (SAS Institute Inc, Cary, NC, USA). Descriptive data for continuous variables are presented as mean with standard deviation. The baseline characteristics of the patient groups were compared by Fisher's exact test for categorical variables. An 
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unpaired t-test was used for continuous variables. The prevalence of VH was estimated by the Kaplan-Meier method and was compared using the log-rank test. A multivariate Cox proportional hazards model was used to adjust for potential confounders and demographic variables. Twosided P values of less than 0.05 were considered to be statistically significant.
Results
We studied 151 DR patients, whose baseline characteristics classified according to the presence or absence of post-revascularization VH (including hyphema and preretinal hemorrhage) are shown in Table 1 . DR patients were grouped into the 2 major categories (NPDR and PDR) according to the status of the worst affected eye at the time of coronary revascularization. Patients with VH were more likely than those without to have PDR (P=0.0058), and lower HbA1c level (P=0.0081) and body weight (P=0.097).
The mean follow-up period from coronary revascularization was 531±416 days. During this time, VH occurred in 24 (15.9%) patients, and 18 (11.9% of the overall total) patients experienced VH within 6 months. The VH rate at 1 year was 14.5% (Figure 1 ): 3 NPDR patients (5.4%) and 21 of 95 PDR patients (22.1%) experienced VH. The 1-year prevalence of VH was higher in PDR patients than in NPDR patients (22.0% vs. 1.9%, P=0.0055, Figure 2) . Table 2 presents the retinal status of the 151 DR patients classified according to the presence or absence of VH after coronary revascularization. A larger proportion of the patients with VH had rubeotic glaucoma (P=0.0096) and a history of vitrectomy (P=0.0029). In total, 8 CABG patients (22.2%) with coronary revascularization experienced VH, as did 16 DES implantation patients (13.9%). However, the prevalence of VH curves did not differ significantly between the patients who had undergone CABG and those who had had DES implantation (Figure 3) . In the multivariate Cox regression analyses adjusted for body weight, DR severity, and HbA1c, PDR and HbA1c at the time of coronary revascularization remained significantly associated with the prevalence of VH (adjusted hazard ratio, 4.19 and 0.58; 95% confidence interval, 1.44-17.8 and 0.39-0.86; P=0.0064 and 0.0043, respectively).
Visual Acuity
The visual acuity following VH ranged from no light sensation to 1.0. Visual acuity had increased in 15 eyes (56.5%), and decreased in 3 eyes (13%) at the last examination. During VH, the visual acuity was 1.0 in 1 (4.3%), between 0. (Figure 4) . In 3 of these 5 eyes, the visual acuity was worse than that before coronary revascularization: in 1 eye, between hand motion and no light sensation; in another, from 0.1 to hand motion; and in the other, from 1.0 to hand motion.
Discussion
The present study revealed that VH was not infrequently seen after coronary revascularization in DR patients and occurred in 75% of the VH patients within 6 months of the procedure. The 1-year prevalence of VH was higher in PDR patients than in NPDR patients. However, the incidence of VH was not significantly associated with the procedure of coronary revascularization (CABG or DES implantation). These findings suggest that both careful pre-and postrevascularization eye treatment and cooperation between cardiol- 
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ogists, cardiac surgeons and ophthalmologists are required for DR patients. Careful follow-up without vitreous surgery is continued if VH occurs, and vitreous surgery is performed in patients in whom spontaneous regression is not observed. Vitrectomy, introduced by Machemer et al, 7 plays a vital role in the management of severe complications of DR. The major indications are nonclearing VH, macula-involving or maculathreatening traction retinal detachment, and combined traction-rhegmatogenous retinal detachment. The Diabetic Retinopathy Vitrectomy Study Research Group reported that for eyes with recent severe VH, early vitrectomy provides a greater chance of prompt recovery of visual acuity than the deferral of vitrectomy for 1 year. 8, 9 Therefore, ophthalmologists would prefer to treat persistent VH as soon as possible. However, they hesitate to treat patients who have had VH after DES implantation for revascularization, because the discontinuation of dual-antiplatelet drugs might cause stent thrombosis and lead to myocardial infarction or death.
Current recommendations by the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions regarding the prevention of stent thrombosis after coronary stent implantation are that patients should be treated with, at minimum, clopidogrel 75 mg and aspirin 325 mg for 1 month after baremetal stent implantation, 3 months after sirolimus DES implantation, 6 months after paclitaxel DES implantation, and ideally, up to 12 months if they are not at high risk for bleeding. 10 Premature discontinuation of antiplatelet therapy markedly increases the risk of stent thrombosis, a catastrophic event that frequently leads to myocardial infarction and/or death. 11, 12 Cardiologists at The University of Tokyo Hospital prescribe dual antiplatelet agents for 1 year, when it is feasible, to patients who have undergone DES implantation. Although VH occurred within 6 months of procedure in 75% of the VH patients in the present study, the antiplatelet agents could not be discontinued in those who underwent DES implantation. However, an adverse effect of this therapy is continuous bleeding 13 and a representative case is shown in Figure 5 . The difficulty in treating VH after PCI with DES Patients who underwent coronary artery bypass surgery (CABG) or percutaneous coronary intervention with drug-eluting stent (DES) implantation were analyzed during the follow-up period only with regard to the primary procedure. The P value was calculated by the log-rank test. 
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implantation is that the prolonged dual antiplatelet therapy is mandatory because of the further potential risk for stent thrombosis. Fortunately, the patient in question did not lose vision, because vitrectomy was performed 6 months after PCI with DES, using a regimen of heparin infusion in a collaborative approach between the ophthalmologists and cardiologists. The dual antiplatelet treatment after coronary revascularization may influence the occurrence of persistent VH. In our study, 3 patients had a decrease in visual acuity after PCI with DES implantation and experienced severe visual disturbance in the eye with VH. In contrast, the patients in whom VH occurred after CABG for revascularization could discontinue antiplatelet therapy. Moreover, the use of aspirin, usually prescribed by the hospital's cardiac surgeons for patients with CABG, did not increase the occurrence of VH or preretinal hemorrhage in DR patients. 14 It is important to avoid adversely affecting the patient's quality of life and to save that life, so in the light of the results of this study, the hospital's cardiologists are choosing CABG rather than PCI for middle-aged DR patients.
PRP is the treatment of choice for high-risk retinopathy. The Diabetic Retinopathy Study first established the benefits of treating eyes with high-risk PDR. 15 Although every PDR patient in the present study who had undergone regular ophthalmologic outpatient clinic treatment received PRP treatment before coronary revascularization, 21 patients had had VH, which implies that coronary artery disease affects the progression of DR.
In the present study the total number of CABG patients was 36, 34 of whom were treated off-pump and 2 were onpump. Of them, 7 experienced VH after off-pump CABG, and 1 after on-pump surgery. The prevalence of VH among the off-pump and on-pump patients did not differ significantly. The CABG procedure did not affect the prevalence of VH, but the number of patients was rather small for a conclusive judgment.
Patients with VH were more likely to have PDR and lower HbA1c levels at the time of coronary revascularization. One possible explanation is that DR patients suffer from diabetic nephropathy. The pharmacokinetics of insulin and other medications change because of decreased kidney metabolism and clearance. 1 The serum creatinine levels tended to be higher in patients with VH than in those without it. In VH patients, hypoglycemia is more frequent and the HbA1c level may decrease. After the coronary intervention, HbA1c levels did not differ significantly between patients with VH and those without VH (7.0±1.2% and 6.8±1.1% 3 months (P=0.56), and 7.0±1.5% and 7.0±1.1% 6 months (P=0.95) after intervention, respectively). The quality of DM treatment after coronary revascularization was reasonably good.
Our results reveal that only 3 NPDR patients experienced VH after coronary revascularization. PRP treatment significantly reduces the risk of severe vision loss from PDR and early PRP treatment also reduces the risk of visual loss in NPDR patients. 16 Good ophthalmic control brought about by regular, strict clinical and angiographic follow-up, as well as adequate treatment, can reduce the risk of VH in eyes with severe NPDR or PDR. 17 Careful pre-and postrevascularization eye treatment and cooperation among the cardiologists, cardiac surgeons and ophthalmologists are required for DR patients.
In our study, the prevalence of VH was high in patients with DR, especially in those with PDR. VH occurred more frequently after revascularization in the PDR patients with rubeotic glaucoma and a history of vitrectomy than in those without. Therefore, the future risk of VH may influence the choice of revascularization strategy for DR patients, and DES implantation may be contraindicated in PDR patients, especially those who have rubeotic glaucoma or a history of vitrectomy. Cardiologists and cardiac surgeons should recognize the high prevalence of VH after coronary revascularization and give this information to DR patients, especially those with rubeotic glaucoma and a history of vitrectomy, during the process of giving informed consent to coronary intervention.
Study Limitations
First, we used a strict criterion for the diagnosis of DM, so some patients with mild DM may have been excluded. Second, in accordance with the protocol of eye screening for DR, most DR patients in this study underwent an eye examination every 6-12 months, and we used the most recent ophthalmologic records up to the time of coronary revascularization to approximate the status of DR at the time of the Figure 5 . Preretinal hemorrhage in a patient with proliferative diabetic retinopathy after drug-eluting stent (DES) implantation. At 35 days after DES implantation, a fundus photograph (A) revealed a preretinal hemorrhage in the right eye. At 6 months after DES implantation, the patient's persistent preretinal hemorrhage suddenly deteriorated and vitreous hemorrhage (VH) occurred because of the continued dual-antiplatelet therapy (B). He underwent vitrectomy immediately after a heparin infusion, because the VH resulted in impaired vision.
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procedure. Therefore, the retinal status at the time of the procedure may have been underestimated. Third, our patient sample was small. A larger and longer follow-up will be required to assess the influence of the stage of DR on VH. Finally, the clinical outcomes were retrospectively evaluated, and so we were unable to estimate precisely the prevalence of VH following coronary revascularization.
Conclusions
VH is not a rare complication following coronary revascularization among DR patients, especially PDR patients. The treatment of VH is important to maintain quality of life, as well as extending the patient's life span. Therefore, careful pre-and postrevascularization eye treatment and cooperation among cardiologists, cardiac surgeons and ophthalmologists are required for DR patients.
